A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Jarskog, L Fredrik

A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. [electronic resource] - Schizophrenia research May 2015 - 136-42 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1573-2509

10.1016/j.schres.2015.01.041 doi


Adult
Antipsychotic Agents--therapeutic use
Benzazepines--therapeutic use
Cognition Disorders--drug therapy
Female
Histamine Antagonists--therapeutic use
Humans
Male
Middle Aged
Neuropsychological Tests
Psychiatric Status Rating Scales
Schizophrenia--complications
Treatment Outcome
Young Adult